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Fluoxetine pretreatment blocks DPAT-induced phase shifts, in vitro
Amanda Wehner

Introduction
Circadian rhythms are the manifestations ofthe roughly twenty-four hour cycle of
behavioral and physiological systems controlled by the internal clock. In mammals, this
internal clock is located in the suprachiasmatic nucleus (SCN). The SCN is a bilateral
nucleus in the hypothalamus, consisting of only about 20,000 neurons. It lies just above
the optic chiasm and on either side of the third ventricle. SCN cells have been shown to
demonstrate rhythmic firing, glucose uptake, and neurotransmitter release. The overall
activity of the organism is influenced by the physiological factors controlled by the SCN
(Herzog and Swartz 2002).
SCN activity does not function on an exactly twenty-four hour cycle; external and
physiological factors are constantly resetting it. These constant adjustments are referred
to as phase shifts. Light input has the strongest impact on SCN rhythmicity. Light input
to the retina reaches the SCN through the optic nerve. The retino-hypothalamic pathway
neurons synapse directly on SCN neurons (Moore 1995). Glutamate is the main
neurotransmitter of this pathway. The presence of light stimulates the release of
glutamate into the SCN, causing the neurons to produce more activity (Rea 1998).
However, light input can be modulated by other SCN afferents.
One of these afferents originates in the midbrain raphe nucleus, widely recognized
for its involvement in the regulation of brain arousal and consciousness. Serotonin is the
main neurotransmitter utilized by this pathway. Activity, through the release of 5-HT, can
modify light-induced-entrainment during the night. During the day, addition of serotonin
or its agonists to the SCN can induce phase advances on their own (Mistlberger, et al.
2000, Morin 1999, and Prosser 2003, and Weber, et al. 1998).

Serotonin acts through many different types of receptors in the SeN and other
circadian rhythms related areas; such as type-lA, 1B, 1D, 2A, and 7 receptors (Barnes
and Sharp 1999, Roca, et al. 1993, and Sumner, et al. 1992). DPAT, a serotonin agonist,
has been shown to cause phase shifts in in vitro SeN experiments (Edgar, et al. 1993).
The 5-HT7 receptor is known to affect the regulation of circadian rhythms (Lovenberg, et
al. 1993), and has been found to exist in relatively high densities in the limbic areas,
including the hypothalamus (Waeber and Moskowitz 1995). Ligands, which bind
exclusively to the 5-HT7 receptor were shown to advance the mean neuronal activity in
the rat SeN (Lovenberg, et al. 1993). Sprouse, et al. showed that the phase resetting
actions of DPAT are sensitive to 5-HT7 receptor antagonists, suggesting this receptor is
the site of DPAT-binding (2004).
While serotonin and it agonists have been shown to induce daytime phase
advances when applied to the SeN in vitro, these effects are not always seen when
applied in vivo (Antle, et al. 2003, Horikawa and Shibaka 2004, and Bobrzynska, et al.
1996). Differing levels of endogenous serotonin present in the SeN in vivo versus in vitro
may cause this discrepancy. The severing of the serotonin afferents during slice
preparation may lower the level of serotonin present in the SeN, leading to an increase in
5-HT receptor expression or sensitivity. Thus, acute administration of 5-HT or 5-HTagonist could cause a phase advance in vitro while the same treatment would have no
effect in vivo.
Fluoxetine is a selective serotonin reuptake inhibitor. Studies have shown that
treatment with fluoxetine causes decreases in light-induced phase delays if serotonin is
not already present in the SeN. If serotonin is already present due to sleep deprivation,

no further decrease in light-induced phase delay is seen, suggesting fluoxetine works
through the serotonin system (Challet, et al. 2001). Sleight and colleagues showed that
treatment of rats with fluoxetine causes a significant reduction in the number of 5-HT7
receptor binding sites in the hypothalamus, suggesting that chronic treatment of
fluoxetine causes the receptor to be down-regulated in the hypothalamus of the rat
(Sleight, et ai. 1995). Pretreatment with fluoxetine should raise the effective level of
serotonin in the slice by blocking the reuptake of released serotonin (Mullins, et ai. 1999).
Duncan, et ai. also showed that chronic antidepressant treatment reduced agonist-induced
phase advances, as with DPAT (1999). In light of these data, we hypothesized that, by
increasing the effective serotonin levels, in the SCN, fluoxetine treatment of the SCN
brain slices would block serotonergic phase shifts. If fluoxetine treatment blocks the in
vitro DPAT-induced phase advances, it provides support for the theory that the difference

between endogenous levels of serotonin in vivo and in vitro is a possible cause for the
different responses to acute serotonin administrations.
Methods
Brain slice preparation

Coronal brain slices (500 !-lm) containing the SCN were prepared during the daytime
from adult, male C57BLlJ6 mice, housed in a 12-hour light/dark cycle, where ZT 0 is
lights on and ZT 12 is lights off. ZT stands for zeitgeberger time. Slices were prepared
between ZT 0-2. Slices were maintained at the interface of a Hatton-style brain slice
chamber (Hatton, et aI., 1980) in which they were perfused continuously with warm
(37°C), oxygenated (95% 0 2/5% CO2), glucose-bicarbonate-supplemented Earle's
Balanced Salt Solution (EBSS; Sigma, St. Louis, MO), pH 7.4-7.5.

Experimental Treatments
The drugs used in phase-shifting experiments were applied during day 1 in vitro by
stopping the perfusion and replacing the medium in the slice chamber with medium
containing the test compound. Following the treatment period, normal medium was
replaced in the slice chamber and perfusion was restored. Fluoxetine was applied for 1
hour from ZTS-6 and (+) 8-hydroxy-2-(di-n-propylamino) tetralin [DPAT] was applied
for 10 minutes starting at ZT 6.
Single unit recordings and data analysis
Single-unit recordings commenced early on day 2 in vitro. For the treatment slices,
recording began approximately 18 hours following treatment. The procedure followed
was described previously (Prosser, et aI., 1993). The spontaneous activity of single SCN
neurons was recorded using glass capillary micro electrodes filled with 3M NaCl. Each
neuron was recorded for approximately 5 minutes, and the data was stored for later
analysis using a DataWave system (DataWave Technologies, Longmont, CO). In general,
four to seven cells were recorded each hour. These firing rates were then used to calculate
2 hour running averages, lagged by 1 hour, to obtain a measure of population neuronal
activity. The time of peak neuronal activity was assessed by visually estimating, to the
nearest quarter hour, the time of symmetrically highest activity. Phase shifts were
calculated as the difference in time of peak of untreated slices vs. drug-treated slices.
Results

Control experiments
The SCN neuronal activity recordings obtained from untreated mouse slices on
nd

the 2 day in vitro demonstrated a peak in activity near mid-subjective day. The mean of

peak activity was ZT 6.0 +/- 0.71 (n=3). An example of an untreated slice's neuronal
rhythm is shown in Figure 1.

DPAT treatment causes phase advances in vitro
One set of experiments consisted of brain slices which were treated for 10
minutes at ZT 6 on day 1 in vitro with 10)lM DPAT, shown in figure 2. These slices
exhibited a mean time of peak activity at ZT 2.85 +/- 0.17 (n=5), indicating a phase
advance of 3.15 hours, which is statistically significant.
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Figure 1. Control. Shown are the 2 hour means +/- SEM
of SCN neuronal activity in a control experiment that
peaked at ZT 6.0 +/- 0.71 (n=3). Horizontal bars: time of
lights off in the colony; dotted line: mean time of peak in
control experiments.

Figure 2. IOIlM DP AT induces phase advance when
applied at ZT 6. Shown are the 2 hour means +/- S. E. M.
of SCN neuronal activity obtained after treatment with 10
IlM DPAT. The mean time of peak after DPAT treatment
was ZT 2.85 +/- 0.17 (n=5), demonstrating a phase
advance of 3.15 hours. Horizontal bars: time of lights off
in the colony; vertical bar: time of drug treatment; dotted
line: mean time of peak in control experiments.

Fluoxetine causes no phase shifts of mouse seN in vitro
Two series of experiments tested the effects of Fluoxetine treatment on the
neuronal activity pattern. In the first series of experiments, the slices were treated with 20
)lM Fluoxetine from ZT5-6 on day 1 in vitro. They exhibited a mean time of peak activity
at ZT 5.0 +/- 0.58 (n=3), which is not a significant phase shift. The results of one of these

experiments are seen in Figure 3. In the second series, the slices were treated with 200
/-lM Fluoxetine from ZT5-6 on day 1 in vitro. These slices showed a mean time of peak
activity at ZT 5.08 +/- 0.1 (n=3), which also does not show a significant phase shift. The
results of one of these experiments are shown in Figure 4.
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Figure 3. Fluoxetine no significant phase shift. Shown are
the 2 hour means +/- SEM of SCN neuronal activity
obtained after treatment with 20llM Fluoxetine. The mean
time of peak activity was ZT 5.0 +/- 0.58 (n=3),
demonstrating no significant phase shift. See figure 2 for
legend.
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Figure 4. Fluoxetine no significant phase shift.
Shown are the 2 hour mean +/-SEM ofSCN
neuronal activity obtained following treatment
with 200llM Fluoxetine. The mean time of peak
activity was ZT 5.08 +/- 0.1 (n=3), demonstrating
no significant phase advance. See figure 2 for
legend.

Pretreatment with Fluoxetine blocks DPAT-induced phase shifts
In the next set of experiments, slices were pretreated from ZT 5-6 with 20 /-lM
Fluoxetine before the 10 minute DPAT treatment. In these experiments, DP AT continued
to induce phase shifts, such as is shown in Figure 5. In the final set of experiments, slices
were pretreated with 200 /-lM Fluoxetine from ZT 5-6, followed by the 10 minute DPAT
treatment. These slices demonstrated a mean time of peak activity at ZT 6.08 +/- 0.1
(n=3), showing a complete block of the DPAT-induced phase advance. These
experiments are represented in Figure 6.
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Figure 5. 20 11M Fluoxetine pretreatment not sufficient
to block DPAT-induced phase advance. Shown are the
2 hour means +/- SEM of SCN neuronal activity
following treatment with 20llM Fuoxetine and IOIlM
DPAT. The mean time of peak activity was ZT 4.0 +/O.IS (n=3), showing a phase advance of 2 hours, which
is not significantly different from the peak activity
following DPAT treatment alone. See figure 2 for
legend.
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Figure 6. Pretreatment with 200 11M Fluoxetine blocks
DPAT-induced phase shift. Shown are the 2 hour
means +/- SEM ofSCN neuronal activity follwing
treatment with 200ilM fluoxetine and 10 11M DPAT.
The mean time of peak activity was ZT 6.0S +/- 0.1
(n=3), showing a phase delay ofO.OS hours. Therefore,
this concentration offluoxetine completely blocked the
phase advance induced by DP AT. See figure 2 for
legend.

Figure 7 summarizes the phase advances seen by all the treatment groups. As seen in the
histogram, DPAT alone causes the most robust phase advance and pretreatment with 200
~M

Fluoxetine completely eliminates this phase advance.
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Figure 7. DPAT-induced phase shifts
are dose-dependently blocked by
fluoxetine. Shown are the mean phase
shifts induced by the different
treatments. The * shows phase shifts
which are significant (p<0.05) vs. the
control.

Discussion
The results of these experiments clearly demonstrate that the DPAT-induced
phase advance can be blocked by pre-treatment with Fluoxetine in a dose-dependent
manner. These results may provide an explanation for the discrepancy between the
effects of in vivo and in vitro treatments with DPAT. Previous studies with in vivo
injection of DPAT into the SeN have shown no phase advances (Antle, et al. 2003),
while work with DPAT treatments in vitro, as seen in this experiment, have shown a
robust phase advance (Prosser 2000).
It is possible that fluoxetine pretreatment blocks in vitro phase advances by DP AT

because it produces conditions that more closely mimic the in vivo environment.
Fluoxetine blocking 5HT reuptake may raise the effective concentration of serotonin
present in the slice. This rise in effective serotonin levels may desensitize the clock to
serotonin, causing the DP AT treatment not to produce a phase shift. One study provides
additional support for this hypothesis. They showed that in vivo 5-HT administration to
the seN induces robust phase advances when animals have been pretreated with a
serotoin antagonist which reduces 5-HT levels in the SeN (Ehlen, et al. 2001). The fact
that lowering the in vivo 5-HT levels allows serotonergic phase shifts to be expressed
lends credence to the hypothesis that the different effects seen in vivo and in vitro are due
to different levels of endogenous serotonin stimulation in the two conditions.
While these experiments show a block of the DPAT-induced phase advance, they
do not show how or at what level the fluoxetine is working to block the phase advance.
The fluoxetine induced increase in effective serotonin concentration may be acting
directly on the receptor, causing a decrease in sensitivity. However, it may also be acting

further down the signaling pathway. Further studies to show the effects of blocking
downstream pathways on the blockage of the phase advance could help to elucidate the
mechanism offluoxetine's effect on the DPAT-induced phase advance. Understanding
how fluoxetine is acting to affect circadian rhythms may help to mitigate or explain side
effects shown in those using fluoxetine as an anti-depressant. If the mechanism of
fluoxetine action can be illuminated, these side effects may be more easily treatable.
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